Education
About Us
Working with TipRanks
Follow Us
Helius Medical Technologies (HSDT)
NASDAQ:HSDT
HSDT Stock Chart & Stats
$3.74
-$0.04(-5.47%)
At close: 4:00 PM EST
$3.74
-$0.04(-5.47%)
Day’s Range― - ―
52-Week Range$2.83 - $1,200.00
Previous CloseN/A
Volume68.49K
Average Volume (3M)1.55M
Market Cap
$183.36M
Enterprise Value-$4.96M
Total Cash (Recent Filing)$124.05M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.03
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-32.89
Shares Outstanding40,299,220
10 Day Avg. Volume1,311,391
30 Day Avg. Volume1,547,142
Financial Highlights & Ratios
PEG Ratio2.86
Price to Book (P/B)1.29K
Price to Sales (P/S)2618.59
P/FCF Ratio-123.27
Enterprise Value/Market Cap-0.03
Enterprise Value/Revenue-5.27
Enterprise Value/Gross Profit-10.61
Enterprise Value/Ebitda0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Sell
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ResultsHSDT announced positive results from the PoNS Therapeutic Experience Program, or PoNSTEP, study for people with multiple sclerosis.
Partnerships And ApprovalsUnitedHealthcare has approved reimbursement for the PoNS device, adding a second private payer to provide coverage.
Bears Say
Financial PerformanceHSDT reported lower-than-expected 1Q25 revenue, as adoption of the PoNS device remains inconsistent.
Reimbursement ChallengesThe ongoing reimbursement headwind continues to limit access to key patient populations and suppress near-term growth.
Helius Medical Technologies News
HSDT FAQ
What was Helius Medical Technologies’s price range in the past 12 months?
Helius Medical Technologies lowest stock price was $2.83 and its highest was $1200.00 in the past 12 months.
What is Helius Medical Technologies’s market cap?
Helius Medical Technologies’s market cap is $183.36M.
When is Helius Medical Technologies’s upcoming earnings report date?
Helius Medical Technologies’s upcoming earnings report date is May 07, 2026 which is in 154 days.
How were Helius Medical Technologies’s earnings last quarter?
Helius Medical Technologies released its earnings results on Nov 18, 2025. The company reported -$32.89 earnings per share for the quarter, beating the consensus estimate of -$50.5 by $17.61.
Is Helius Medical Technologies overvalued?
According to Wall Street analysts Helius Medical Technologies’s price is currently Overvalued.
Does Helius Medical Technologies pay dividends?
Helius Medical Technologies does not currently pay dividends.
What is Helius Medical Technologies’s EPS estimate?
Helius Medical Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Helius Medical Technologies have?
Helius Medical Technologies has 40,299,220 shares outstanding.
What happened to Helius Medical Technologies’s price movement after its last earnings report?
Helius Medical Technologies reported an EPS of -$32.89 in its last earnings report, beating expectations of -$50.5. Following the earnings report the stock price went down -6%.
Which hedge fund is a major shareholder of Helius Medical Technologies?
Currently, no hedge funds are holding shares in HSDT
Helius Medical Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
― (―)
― (―)
Crowd Wisdom
Positive
Last 7 Days ▲ 5.4%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-98.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.77%
Trailing 12-Months
Company Description
Helius Medical Technologies
Helius Medical Technologies (HSDT) is a medical technology company focused on developing innovative therapies and devices for neurological diseases. The company specializes in the commercialization of its portable, non-invasive platform technology, which is designed to enhance neurological function in patients with certain conditions, particularly those suffering from traumatic brain injury (TBI) and other neurological disorders. Helius aims to improve patient outcomes through its products that leverage electrical stimulation to promote neural recovery.
HSDT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements in fundraising and strategic advocacy, leading to increased Solana holdings and positive clinical outcomes for the PoNS device. However, these positives were offset by substantial financial losses and increased operating expenses, with the digital asset treasury market showing signs of cooling.View all HSDT earnings summariesTechnical Analysis
Ownership Overview
0.96%
Insiders
<0.01% Mutual Funds
22.18% Other Institutional Investors
76.86% Public Companies and
Individual Investors